Arcutis Biotherapeutics, Inc. (ARQT) vs Enliven Therapeutics, Inc. (ELVN)
A side-by-side comparison of Arcutis Biotherapeutics, Inc. and Enliven Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARQT
Arcutis Biotherapeutics, Inc.
$25.07HealthcareDelayed quote: Oct 6, 2026, 9:35 AM EDT
ELVN
Enliven Therapeutics, Inc.
$45.38HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — ARQT vs ELVN
growth of $100 · dividends reinvested · last 7yARQT +12.7% (+1.7%/yr)ELVN -24.2% (-3.9%/yr)ARQT compounded faster over this window
ARQT ELVN
ARQT vs ELVN: by the numbers
- •ELVN is the larger company ($3.24B vs $3.14B market cap).
- •ARQT is profitable (6.15% net margin) while ELVN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ARQT | ELVN |
|---|---|---|
| P/E ratio | 120.22 | N/A |
| Forward P/E | 50.42 | N/A |
| P/S ratio | 6.76 | N/A |
| P/B ratio | 14.21 | 3.62 |
| EV / EBITDA | 86.43 | N/A |
| FCF yield | 1.25% | N/A |
Profitability
| Metric | ARQT | ELVN |
|---|---|---|
| Gross margin | 91.14% | 0.00% |
| Operating margin | -3.25% | 0.00% |
| Net margin | 6.15% | 0.00% |
| ROE | 12.93% | -11.83% |
| ROIC | 9.95% | -13.88% |
Growth (annualized)
| Metric | ARQT | ELVN |
|---|---|---|
| Total return CAGR (5Y) | -0.28% | 24.57% |
Frequently asked
- Is ARQT or ELVN more profitable?
- ARQT runs the higher net margin — ARQT at 6.15% versus ELVN at 0.00%.
- How have ARQT and ELVN total returns compared?
- Over the past 5 years, ARQT delivered -0.28% and ELVN delivered 24.57% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arcutis Biotherapeutics P/E ratioArcutis Biotherapeutics ROEEnliven Therapeutics ROEArcutis Biotherapeutics operating marginEnliven Therapeutics operating marginArcutis Biotherapeutics revenue growthEnliven Therapeutics revenue growthArcutis Biotherapeutics free cash flowEnliven Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.